Skip to content
Study details
Enrolling now

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NRG Oncology
NCT IDNCT06500455ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

269

Study length

about 3.6 years

Ages

18+

Locations

256 sites in AR, AZ, CA +34

What this study is about

This trial is testing whether a longer duration of radiation therapy (fractionated stereotactic radiosurgery) is more effective than usual radiation therapy (stereotactic radiosurgery) for treating cancer that has spread to the brain. The goal is to determine if this new approach can improve outcomes for patients with this type of cancer.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Fractionated Stereotactic Radiation Therapy
  • 2.Receive Stereotactic Radiosurgery
  • 3.Undergo Computed Tomography
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Incidence of adverse events (AEs), Intracranial progression-free survival (IPFS), Overall survival

Procedures

imaging, radiation

Body systems

Oncology